

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:
22-264

OTHER ACTION LETTER(s)



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 22-264

COMPLETE RESPONSE

Ortho-McNeil-Jansen Pharmaceuticals, Inc.
Attention: Rodney Malchow
Associate Director, Regulatory Affairs
1125 Trenton-Harbourton Road
P.O. Box 200
Titusville, N.J. 80560

Dear Mr. Malchow:

Please refer to your new drug application (NDA) dated October 25, 2007, received October 26, 2007, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Invega Sustenna (paliperidone palmitate) (b) (4)

We acknowledge receipt of your submissions dated:

December 12, 2007	December 21, 2007	January 9, 2008	February 21, 2008
February 25, 2008	February 27, 2008(2)	May 2, 2008	May 12, 2008
May 21, 2008	May 28, 2008	May 29, 2008	June 2, 2008
June 3, 2008	June 13, 2008	June 26, 2008	July 2, 2008
July 11, 2008	July 15, 2008(2)	August 20, 2008	

We also acknowledge receipt of your amendment dated August 12, 2008, which was not reviewed for this action. You may incorporate applicable sections of the amendment by specific reference as part of your response to the deficiencies cited in this letter.

We have completed the review of your application, and have determined that we cannot approve this application in its present form. We have described below our reasons for this action and, where possible, our recommendations to address these issues.

PRODUCT QUALITY

1. The Drug Master File (b) (4) for (b) (4) has been found to be inadequate to support the NDA.

2. It is FDA policy that the strength of the drug substance has to be provided as part of the established name. The proposal to just remove the reference to strength (mg) from the product name is not sufficient. The historical evidence provided to justify your proposal is not sufficient because most products listed were approved quite awhile ago and do not reflect current practices. According to information you provided in the original NDA submission “paliperidone palmitate dissolves slowly after intramuscular injection before being hydrolyzed to paliperidone and absorbed into the systemic circulation”, which indicates that paliperidone palmitate is a prodrug and that the palmitate ester exerts a biopharmaceutic effect.
3. Establish an acceptance criteria equal to or less than ^(b)₍₄₎ ppm for the two genotoxic impurities, ^(b)₍₄₎ and ^(b)₍₄₎.
4. ^(b)₍₄₎
5. The syringe barrel should contain calibrated markings to indicate the appropriate volume of drug product in the syringe and allow for partial doses to be given from the syringe.
6. A transparent label that allows for the viewing of the syringe calibration marks and drug product should be used for labeling of the syringes.

LABELING

Submit draft labeling that incorporates revisions in the attached labeling. In addition, submit updated content of labeling [21 CFR 314.50(l)(1)(i)] in structured product labeling (SPL) format as described at <http://www.fda.gov/oc/datacouncil/spl.html>.

When responding to this letter, submit labeling that includes all previous revisions, as reflected in the most recently approved package insert. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should include annotations with the supplement number for previously-approved labeling changes.

Please submit draft carton and container labeling revised as follows:

Syringe Labeling

1. The product strength should be relocated so that it no longer appears to be part of the proprietary name (e.g., TRADENAME 25 mg). Instead, the product strength should follow or be immediately adjacent to the established name.
2. Express the strengths of the prefilled syringes in terms of milligrams per total volume (e.g., 25 mg/0.25 mL, 50 mg/0.5 mL, 75 mg/0.75 mL, and 100 mg/mL) to decrease the potential for dose calculation errors. This information should be displayed on the syringe label and immediately following or adjacent to the established name.
3. If space permits, ^(b)₍₄₎

[Redacted] (b) (4)

Carton Labeling

1. Revise the fonts of the proprietary and established names so that the established name is at least one half the size of the proprietary name per 21 CFR 201.10(g)(2).
2. The product strength should be relocated so that it no longer appears to be part of the proprietary name (e.g., TRADENAME 25 mg). Instead, the product strength should follow or be immediately adjacent to the established name.
3. Express the strengths of the prefilled syringes in terms of milligrams per total volume (e.g., 25 mg/0.25 mL, 50 mg/0.5 mL, 75 mg/0.75 mL, and 100 mg/mL) to decrease the potential for dose calculation errors. This information should be prominently displayed on the principal display panel immediately following or adjacent to the established name so that it is not overlooked by the reader.

4. [Redacted] (b) (4)

Dissolution Method and Specification

The following dissolution method and specification are acceptable for Invega Sustenna (paliperidone palmitate) [Redacted] (b) (4)

Parameter	Dissolution Method and Specification	
Apparatus Type	USP Type II (paddle)	
Media	0.001 M HCL containing 0.489% Polysorbate 20 (Tween®20)	
Volume	900 ml	
Temperature	25 ± 0.5 °C	
Frequency	50 rpm	
Sampling Times	8,20 and 45 minutes	
Acceptance Criteria	8 minutes	(b) (4) of Label Claim
	20 minutes	(b) (4) of Label Claim
	45 minutes	(b) (4) of Label Claim
Analysis	HPLC UV detection	

SAFETY UPDATE

When you respond to the above deficiencies, include a safety update as described at 21 CFR 314.50(d)(5)(vi)(b). The safety update should include data from all nonclinical and

clinical studies/trials of the drug under consideration regardless of indication, dosage form, or dose level.

1. Describe in detail any significant changes or findings in the safety profile.
2. When assembling the sections describing discontinuations due to adverse events, serious adverse events, and common adverse events, incorporate new safety data as follows:
 - Present new safety data from the studies for the proposed indication using the same format as the original NDA submission.
 - Present tabulations of the new safety data combined with the original NDA data.
 - Include tables that compare frequencies of adverse events in the original NDA with the retabulated frequencies described in the bullet above.
 - For indications other than the proposed indication, provide separate tables for the frequencies of adverse events occurring in clinical trials.
3. Present a retabulation of the reasons for premature study discontinuation by incorporating the drop-outs from the newly completed studies. Describe any new trends or patterns identified.
4. Provide case report forms and narrative summaries for each patient who died during a clinical study or who did not complete a study because of an adverse event. In addition, provide narrative summaries for serious adverse events.
5. Describe any information that suggests a substantial change in the incidence of common, but less serious, adverse events between the new data and the original NDA data.
6. Provide updated exposure information for the clinical studies/trials (e.g., number of subjects, person time).
7. Provide a summary of worldwide experience on the safety of this drug. Include an updated estimate of use for drug marketed in other countries.
8. Provide English translations of current approved foreign labeling not previously submitted.

PROPRIETARY NAME

The Division of Medication Error Prevention and Analysis (DMEPA) and the Division of Psychiatry Products do not object to the use of the proprietary name, Invega Sustenna, for

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.